Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

President Trump’s administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare Advantage and Part D policies. One day after the Senate confirmed Dr ...

The May 26 front-page article “Patients face new hurdles to affordable obesity drugs” highlighted significant barriers patients and providers face in accessing GLP-1 and dual GLP-1/GIP ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Key takeaways: On April 4, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026. Medical societies plan to advocate for passage of the Treat ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

The Biden administration’s rule would have expanded access to obesity drugs, including pricey GLP-1 drugs, to an estimated 3.4 million people on Medicare and 4 million people in Medicaid.

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

The first significant rift within MAGA under Trump 2.0 emerged with the passage of the Big Beautiful Bill, which extended the ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

The Biden administration proposal on obesity drugs. In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in ...